Microcap Ledger Arcadia Biosciences, Inc. $RKDA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Crude Petroleum & Natural Gas
- Headquarters
- Dallas, TX
- Fiscal year end
- December 31
- Shares outstanding
- 2,409,211 [10-Q 2026-08-13]
What the company doesAI summary of filing
Arcadia Biosciences develops and sells Zola coconut water products, which are sourced from Thailand and sold through grocery retailers and foodservice distributors across the United States. The company previously developed wheat-based agricultural traits that it commercialized through trait licensing and royalty agreements, but has divested substantially all of these assets as of 2024 and 2025. Arcadia is a revenue-generating company with net losses of $2.3 million for the year ended December 31, 2025, an accumulated deficit of $281.2 million, and substantial doubt about its ability to continue as a going concern. The company had eight employees as of December 31, 2025. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.54M | −$10.65M | −$1.42M | $4.18M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $4.86M | −$2.34M | −$4.70M | $259.0K | [10-K 2026-03-26] |
| FY ended Dec 2024 | $5.04M | −$7.04M | −$9.63M | $4.24M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$709.0K
- Cash runway Estimate
- ~17.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-23 | 1,367,040 | [10-K/A 2025-04-30] |
| 2025-05-01 | 1,367,040 | [10-Q 2025-05-08] |
| 2025-08-07 | 1,367,040 | [10-Q 2025-08-14] |
| 2025-10-31 | 1,373,120 | [10-Q 2025-11-07] |
| 2026-03-19 | 2,056,884 | [10-K 2026-03-26] |
| 2026-04-23 | 2,056,884 | [10-K/A 2026-04-30] |
| 2026-05-07 | 2,056,884 | [10-Q 2026-05-14] |
| 2026-08-06 | 2,409,211 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-06-26; declared effective 2026-07-08 [S-3 2026-06-26]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-04. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-04] |
| 2026-08-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-10] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-15 | 8-K | Director or officer change; Shareholder vote results |
| 2026-09-04 | 8-K | Listing notice or transfer |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-10 | DEF 14A | Proxy statement |
| 2026-08-10 | 8-K | Listing notice or transfer |
| 2026-07-31 | PRE 14A | Proxy statement |
| 2026-07-09 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-02 | 8-K | Director or officer change; Other events |
| 2026-06-26 | S-3 | Registration statement |
Alerts for $RKDA
Email me when Arcadia Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.